Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Prostatic Neoplasms 12Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Patients With T1-4 Advanced Prostate Cancer 1Osteoporosis 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1Hot Flashes 1Carcinoma, Lobular 1Breast Diseases 1Breast Cancer Invasive 1Anemia 1

Interventions

pyrotinib 4Letrozole 4Trastuzumab 3Docetaxel 3Anastrozole 3exemestane 2Epirubicin 2Drug Evaluation 2Doxorubicin 2Cyclophosphamide 2Capecitabine 2Aromatase Inhibitors 2palbociclib 1abemaciclib 1Vinorelbine 1Tomography, X-Ray Computed 1Tamoxifen 1Surgimend 1Sodium Chloride 1Paclitaxel 1Mammaplasty 1Liquid Biopsy 1Lead 1Lapatinib 1Goserelin 1Fulvestrant 1Drug Therapy 1Cryotherapy 1Carboplatin 1Botulinum Toxins, Type A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Diseases × Goserelin × Clear all
NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown
200 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡